Clinical Trials Directory

Trials / Terminated

TerminatedNCT00535015

Safety and Efficacy Study of Betamarc to Treat Loss of Weight and Appetite in Non-Small Cell Lung Cancer

A Randomized, Double-Blind, Pilot Study Comparing the Safety and Efficacy of Betamarc Plus Chemotherapy to Chemotherapy Alone in the Prevention and Treatment of CACS in Patients With Advanced NSCLC

Status
Terminated
Phase
Phase 2
Study type
Interventional
Enrollment
70 (estimated)
Sponsor
Anaborex · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine whether Betamarc is effective in improving the appetite and reversing weight loss in patients with advanced Non-Small Cell Lung Cancer.

Conditions

Interventions

TypeNameDescription
DRUGBetamarc2 tabs BID

Timeline

Start date
2007-10-01
Primary completion
2008-06-01
Completion
2008-08-01
First posted
2007-09-26
Last updated
2008-07-22

Locations

6 sites across 2 countries: China, Taiwan

Source: ClinicalTrials.gov record NCT00535015. Inclusion in this directory is not an endorsement.

Safety and Efficacy Study of Betamarc to Treat Loss of Weight and Appetite in Non-Small Cell Lung Cancer (NCT00535015) · Clinical Trials Directory